Emerging Evidence Supports SGLT2 Inhibitors, GLP-1 Receptor Agonists, and MRBs for Cardiorenal Protection in Type 1 Diabetes.
Emerging Evidence for Cardiorenal Protection with Sodium-Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes.
Abstract
Review summarizes emerging data on SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor blockers for cardiovascular and renal protection in Type 1 Diabetes.